Skip to main content
logo
Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
20.52
-0.93 (-4.34%)
Oct 30, 2026, 10:37 AM EDT - Market open

Cue Biopharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
37.6627.479.295.491.2514.94
Revenue Growth
354.44%195.75%69.16%340.96%-91.67%373.68%
Gross Profit
-37.34-7.38-23.61-35.31-34.05-26.41
Operating Income
-98.64-26.52-41.59-51.99-53.5-43.71
Net Income
-164.11-26.6-40.67-50.73-53.01-44.16
Earnings Per Share
-36.22-8.42-21.66-33.26-44.61-42.35
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
17.4128.2323.3948.876.2964.37
Total Debt
3.084.28.8814.719.3210.05
Net Cash (Debt)
14.3424.0314.5134.1156.9754.32
Net Cash Growth
-29.47%65.60%-57.45%-40.14%4.89%-30.11%
Net Cash Per Share
3.167.617.7322.3647.9452.09

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-50.05-21.69-36.33-39.96-41.81-38.84
Capital Expenditures
-0.12-0.18-0.07--0.17-0.91
Free Cash Flow
-50.17-21.86-36.4-39.96-41.98-39.75
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-99.15%-26.86%-254.21%---176.73%
Operating Margin
-261.97%-96.56%-447.86%-947.03%-4297.35%-292.56%
Pretax Margin
-434.49%-95.03%-437.97%-924.10%-4257.83%-292.25%
Profit Margin
-435.82%-96.85%-437.97%-924.10%-4257.83%-295.56%
FCF Margin
-133.23%-79.60%-391.89%-727.89%-3371.65%-266.04%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
4.141.017.4421.7098.5324.04